CD19 and congenital rubella syndrome: Studies indicate that factors such as previous neurological compromise, ALL, pre-CART infusion tumor load, lymphodepletion strategies, elevated CD19+ cell counts in bone marrow, high CAR-T cell doses, and the severity of CRS all contribute to elevating the risk of ICANS onset (52, 129, 146, 151).